Bionano Genomics Files Proxy Materials

TL;DR

BIONANO GENOMICS (BNGO) FILED PROXY DOCS - NO FEE REQUIRED, FY ENDS DEC 31

AI Summary

Bionano Genomics, Inc. filed a Definitive Additional Materials proxy statement on October 3, 2024. This filing is related to the company's proxy materials and does not involve a fee, as indicated by the 'No fee required' checkbox. The filing is for the fiscal year ending December 31st.

Why It Matters

This filing provides shareholders with important information regarding company governance and voting matters, which is crucial for their participation in corporate decisions.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain new financial information or strategic changes that would inherently increase risk.

Key Players & Entities

• Bionano Genomics, Inc. (company) — Registrant
• 20241003 (date) — Filing Date
• 1231 (date) — Fiscal Year End

FAQ

Filing Documents

• ny20036676x1_defa14a.htm (DEFA14A) — 18KB
• footer.jpg (GRAPHIC) — 22KB
• image01.jpg (GRAPHIC) — 6KB
• logo_bionano.jpg (GRAPHIC) — 11KB
• 0001140361-24-042655.txt ( ) — 73KB

Forward-Looking Statements of Bionano Genomics

Forward-Looking Statements of Bionano Genomics This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "estimate," "expect," "may," "plan," "will" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the date for the reconvened meeting, and the potential negative impacts to the company if stockholders do not approve the issuance of common stock upon exercise of the warrants. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of approving the issuance of common stock upon exercise of the warrants; the impact of adverse geopolitical and macroeconomic events, such as recent and potential future bank failures and the ongoing conflicts between Ukraine and Russia and Israel and Hamas, on our business and the global economy; general market conditions, including inflation and supply chain disruptions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a "going concern"; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and u

View Full Filing

View this DEFA14A filing on SEC EDGAR